Last week, the OIG posted two important issuances on Direct to Consumer drug programs, including TrumpRx – a Special Advisory Bulletin and a Request for Information (RFI). These issuances follow the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results